- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01678365
Safety and Efficacy of Single Daily Dose of Ceftriaxone and Metronidazole for Treatment of Complicated Appendicitis in Children
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study was conducted at the Pediatric Surgery Department at HaEmek Medical Center, Afula, Israel. Included were children age 1-14 years with complicated appendicitis that was defined by one of the followings: 1. Demonstration by abdominal ultrasound and/or computed tomography of appendix perforation and/or peri-appendicular abscess 2. Demonstration by abdominal ultrasound of free fluid, and signs of diffuse peritoneal irritation in the right lower quadrant of the abdomen 3. At surgery performed for suspected non complicated appendicitis. In a patient with perforate appendicitis that was diagnosed at surgery, appendectomy was performed by one of the 4 senior pediatric surgeons on call at the time of the child's admission. Exclusion criteria were: documented allergy to any of the study medications, acute or renal insufficiency at admission, and severe septic shock at admission.
Therapeutic approach: After the diagnosis of complicated appendicitis was established, patients were randomly assigned to therapy with either once daily of ceftriaxone and metronidazole or ampicillin, gentamicin and metronidazole. Therapy was change to piperacillin/tazobactam in patients who were still febrile at day 7-10 of the admission (if not given before), based on the clinical situation, and in all febrile patients at 11 day of the admission . All patients had also been treats after inclusion with pain control medications, no oral food or fluid , and intravenous hydration as necessary. Nasogastric tubes were not used routinely. On the fifth admission day patients who were stable, a febrile, could tolerate diet and had Complete blood count within normal limits were discharged home with oral amoxicillin/clavulanate therapy for further 7 days.
Follow-up at the admission: CBC and renal and liver function tests were obtained before starting the antibiotic treatment and repeated on day 4 in all patients. In the group treated with AGM, serum trough gentamicin concentration was drawn before the fourth dose with normal level considered as < 2 mcg/ml. Other blood studies were performed based on the discretion of the attending physician based on the patient's clinical status. For patients who were either febrile or had leukocytosis, at day 5 of therapy abdominal ultrasound was obtained to assess for the presence of an abscess. Patients in whom abscesses were delectated undergone per coetaneous drainage (when possible). The original antibiotic regimen was either continued or changed to piperacillin/tazobactam based on the clinical situation. Patients, in whom appendectomy had not been done at admission, were readmitted for appendectomy at 6 weeks. All patients had been followed for a year since the admission for signs of intra abdominal complication such: repeat abscess formation, repeat admission, obstruction etc.
Data collection: Data were recorded were: patient's age, weight, gender, maximum daily temperature, duration of fever, results of complete blood count, renal and liver function tests, gentamicin levels (where applicable), intra abdominal complications and duration of hospitalization. The outcome variables included maximum daily temperatures for each of the first 10 postoperative days, time to initial oral intake, length of hospitalization, length of antibiotic therapy, abscess formation rate, need to change antibiotic regimen, wound infection rate, and any abnormal findings during the follow-up visits.
Statistical analysis: Since data in the literature show that there is no difference of the length of stay in between the 2 regimens (in children with complicated appendicitis following operation), and most studies included relatively low number of patients, no power analysis was calculated. The difference between various parameters in the two treatment groups were assessed by 2 independent sample T tests or Fisher exact tests for categorical data and 2 independent sample t test or the Mann Whitney test for continuous data. Descriptive statistics were calculated as mean ± SD.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Afula, Israel, 18101
- Pediatric Surgery Department, HaEmek Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Children age 1-14 years CA that was defined by one of the followings:
- Demonstration by abdominal ultrasound (US) and/or computed tomography (CT) of appendix perforation and/or peri-appendicular abscess
- Demonstration by abdominal ultrasound (US) of free fluid, and signs of diffuse peritoneal irritation in the right lower quadrant of the abdomen 3
Exclusion Criteria:
- Documented allergy to any of the study medications, acute or renal insufficiency at admission, and severe septic shock at admission.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ceftriaxone and metronidazole for complicated appendicitis.
Children with complicated appendicitis treated with single daily dose of ceftriaxone and metronidazole.
|
|
Active Comparator: Ampicillin, gentamicin, and metronidazole
Children with complicated appendicitis treated with ampicillin, gentamicin, and metronidazole
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Length of stay (days)
Time Frame: From admission to discharge from of first admission (if there are more than one), an expected average 2 weeks
|
From admission to discharge from of first admission (if there are more than one), an expected average 2 weeks
|
Change of primary antibiotic regimen to Piperacillin/tazobactam
Time Frame: From admission to discharge from of first admission (if there are more than one), an expected average 2 weeks
|
From admission to discharge from of first admission (if there are more than one), an expected average 2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of new intrabdominal abcesses
Time Frame: From admission to discharge from of first admission (if there are more than one), an expected average 2 weeks
|
From admission to discharge from of first admission (if there are more than one), an expected average 2 weeks
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Re hospitalization due to intra abdominal abcess formation
Time Frame: Within 2 years after day of discharge
|
Within 2 years after day of discharge
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Infections
- Gastrointestinal Diseases
- Gastroenteritis
- Intestinal Diseases
- Cecal Diseases
- Intraabdominal Infections
- Appendicitis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Protein Synthesis Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- Metronidazole
- Ceftriaxone
- Ampicillin
- Gentamicins
Other Study ID Numbers
- 043-07-EMC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Complicated Appendicitis
-
University of MichiganCompletedAppendicitis | Complicated Appendicitis | Perforated Appendicitis | Ruptured AppendicitisUnited States
-
Johns Hopkins All Children's HospitalCompleted
-
Phoenix Children's HospitalTerminatedComplicated Appendicitis | Perforated AppendicitisUnited States
-
Zealand University HospitalRecruitingComplicated AppendicitisDenmark
-
Tetraphase Pharmaceuticals, Inc.CompletedComplicated Appendicitis | Complicated Intra-abdominal InfectionsUkraine, United States, Bulgaria, Romania, Estonia, Russian Federation, Lithuania, Hungary, Latvia, Georgia, Czechia
-
Sohag UniversityRecruiting
-
Haramaya UnversityCompleted
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingComplicated Appendicitis | Laparoscopic Appendectomy | Periappendicular AbscessSpain
-
Feng JiexiongCompleted
-
Centre Hospitalier Universitaire, AmiensRecruiting
Clinical Trials on ceftriaxone, metronidazole/ampicillin, gentamicin, and metronidazole
-
Michael Cohen-WolkowiezThe Emmes Company, LLCCompleted
-
Children's Mercy Hospital Kansas CityCompletedPerforated AppendicitisUnited States
-
Merck Sharp & Dohme LLCCompletedSurgical Site Infection | Infection
-
Merck Sharp & Dohme LLCCompletedComplicated Intra-abdominal Infection
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedCholecystitis | Appendicitis | Diverticulitis | Intra-Abdominal Abscess | Intra-Abdominal Infection | PeritonitisItaly, Spain, China, France, Switzerland, Australia, Denmark, Finland, Germany, Greece, Hong Kong, India, Philippines, Portugal, Saudi Arabia, South Africa, Taiwan, Turkey, United Kingdom
-
Makerere UniversityRecruitingHIV-1-infection | Malnutrition, ChildUganda
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedCross Infection | Cholecystitis | Appendicitis | Diverticulitis | PeritonitisUnited States, Canada, Chile, Argentina, Brazil, Mexico
-
Merck Sharp & Dohme LLCCompleted
-
PfizerCompletedIntra-abdominal InfectionsJapan
-
United States Naval Medical Center, PortsmouthUnknown